Research Paper Volume 16, Issue 1 pp 267—284

A novel disulfidptosis-related lncRNAs signature for predicting survival and immune response in hepatocellular carcinoma

class="figure-viewer-img"

Figure 6. Differential analysis of immune cells, immune function, immune checkpoints and immunotherapy outcome between high- and low-risk groups. (A) The stromal, immune, and ESTIMATE scores between the two groups. (B, C) Differences in the infiltration of immune cells between the two groups. (D) Comparison of immune functions between two groups. (E) Differences in the expression of immune checkpoints between the two groups. (F) TIDE in the two groups. Abbreviation: TIDE: evaluation of tumor immune dysfunction and exclusion. *p < 0.05, **p < 0.01, ***p < 0.001.